Exploration of the System-Level Mechanisms of the Herbal Drug FDY003 for Pancreatic Cancer Treatment: A Network Pharmacological Investigation

Author:

Lee Ho-Sung12ORCID,Lee In-Hee1,Kang Kyungrae2,Park Sang-In3,Jung Minho4,Yang Seung Gu5,Kwon Tae-Wook2,Lee Dae-Yeon12ORCID

Affiliation:

1. The Fore, 33 Saemunan-ro 5ga-gil, Jongno-gu, Seoul 03170, Republic of Korea

2. Forest Hospital, 33 Saemunan-ro 5ga-gil, Jongno-gu, Seoul 03170, Republic of Korea

3. Forestheal Hospital, 173 Ogeum-ro, Songpa-gu, Seoul 05641, Republic of Korea

4. Forest Hospital, 129 Ogeum-ro, Songpa-gu, Seoul 05549, Republic of Korea

5. Kyunghee Naro Hospital, 67, Dolma-ro, Bundang-gu, Seongnam 13586, Republic of Korea

Abstract

Pancreatic cancer (PC) is the most lethal cancer with the lowest survival rate globally. Although the prescription of herbal drugs against PC is gaining increasing attention, their polypharmacological therapeutic mechanisms are yet to be fully understood. Based on network pharmacology, we explored the anti-PC properties and system-level mechanisms of the herbal drug FDY003. FDY003 decreased the viability of human PC cells and strengthened their chemosensitivity. Network pharmacological analysis of FDY003 indicated the presence of 16 active phytochemical components and 123 PC-related pharmacological targets. Functional enrichment analysis revealed that the PC-related targets of FDY003 participate in the regulation of cell growth and proliferation, cell cycle process, cell survival, and cell death. In addition, FDY003 was shown to target diverse key pathways associated with PC pathophysiology, namely, the PIK3-Akt, MAPK, FoxO, focal adhesion, TNF, p53, HIF-1, and Ras pathways. Our network pharmacological findings advance the mechanistic understanding of the anti-PC properties of FDY003 from a system perspective.

Funder

Ministry of Science ICT and Future Planning

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

Reference205 articles.

1. Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;H. Sung;CA: A Cancer Journal for Clinicians,2020

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;T. Conroy;New England Journal of Medicine,2011

3. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer;T. Conroy;New England Journal of Medicine,2018

4. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer;A. Adamska;Advances in Biological Regulation,2018

5. Complementary Chinese herbal medicine therapy improves survival of patients with pancreatic cancer in taiwan: a nationwide population-based cohort study;Y. T. Kuo;Integrative Cancer Therapies,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3